-The Hindu Business Line The laws concerned are riddled with loopholes. A mandatory, enforceable code for ethical pharmaceutical marketing is a must The recent kerfuffle over a particular brand of the painkiller paracetamol 650 mg tablet is not really over the particular brand as much as about the unethical marketing tactics of the pharmaceutical industry in India. Gone are the days when a mere ball-point pen or a diary from a medical representative...

-Down to Earth No regulation on marketing strategies by drug companies has created a medical autocracy, the Dolo-650 controversy shows If you had to take paracetamol 650 milligrams instead of paracetamol 500 mg three times a day during the COVID-19 pandemic, you may be familiar with the drug called Dolo-650. The drug is prescribed for reducing fever and pain, but the medicine possibly reached you thanks to its manufacturer’s market strategy. A petition...

-TheWire.in The petition alleged that to ensure a higher profit margin, the company manufacturing Dolo tablets distributed freebies to doctors to prescribe the 650 mg drug.  New Delhi: The Supreme Court Thursday, August 18 was told by an NGO that the Central Board of Direct Taxes (CBDT) has accused the pharma company manufacturing paracetamol drug ‘Dolo’ of distributing Rs 1,000 crore freebies to doctors for prescribing a dosage of its 650 mg...

-The Telegraph Drug helps patients recover from fever in an average of three days and from cough in four days A painkiller called indomethacin prescribed for arthritis and spondylitis is an effective treatment for mild or moderate Covid-19, Chennai-based researchers have told India’s apex health research agency, seeking its inclusion in Covid-19 treatment guidelines. The researchers have submitted what they claim are “striking” study results, indicating that patients of mild or moderate Covid-19...

On Janaushadhi Diwas this year (i.e., March 7th, 2022), Prime Minister Shri Narendra Modi stated that the poor and the middle-class benefited from the 'Jan Aushadhi Kendras' that were set up to provide generic drugs at affordable prices. He said that the poor and the middle class saved around Rs.13,000 crore through these stores during the COVID-19 pandemic. In the wake of COVID 19 crisis, the 'Bureau of Pharma PSUs of India'...